Chimerix (NASDAQ:CMRX) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a report released on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reissued a “neutral” rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Chimerix stock opened at $8.46 on Friday. The firm has a market cap of $760.86 million, a PE ratio of -9.00 and a beta of 0.32. The firm’s 50 day moving average price is $4.74 and its two-hundred day moving average price is $2.51. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.48.

Insider Buying and Selling

In related news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 20,760 shares of company stock valued at $91,175. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CMRX. Bender Robert & Associates bought a new position in Chimerix in the 4th quarter worth $37,000. Susquehanna Fundamental Investments LLC bought a new stake in Chimerix in the 4th quarter valued at $59,000. Jane Street Group LLC acquired a new stake in Chimerix in the 4th quarter worth $62,000. Diadema Partners LP acquired a new stake in Chimerix in the 4th quarter worth $101,000. Finally, Squarepoint Ops LLC acquired a new stake in Chimerix in the 4th quarter worth $130,000. Institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.